ArticleTargeted oncology2018

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Maria Di Bartolomeo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.